CPXX News Alert Celator Pharma (CPXX) 1.95 12/13/2014 06:17:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Celator Pharma (CPXX) 1.95 $CPXX

Celator® Pharmaceuticals Presents Data on CPX-351 at the 56th American Society of Hematology Annual Meeting
PR Newswire - Wed Dec 10, 7:30AM CST
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced the presentation of data on its lead product candidate, CPX-351 (cytarabine:daunorubicin) Liposome for Injection, at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition in San Francisco, held December 6-9, 2014.
CPXX: 1.95 (unch)

Celator® Pharmaceuticals Announces Data And Safety Monitoring Board Recommendation To Continue Phase 3 Study Of CPX-351
PR Newswire - Mon Dec 01, 7:30AM CST
EWING, N.J., Dec. 1, 2014 /PRNewswire/-- Celator Pharmaceuticals, Inc. (NASDAQ: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that the independent Data and Safety Monitoring Board (DSMB) for the Company's Phase 3 clinical study of CPX-351 (cytarabine:daunorubicin) Liposome for Injection versus the conventional cytarabine and daunorubicin treatment regimen (commonly referred to as 7+3) as first-line therapy in older patients with high-risk (secondary) acute myeloid leukemia (AML), has completed a planned safety review and recommended that the study continue as planned without any modifications.
CPXX: 1.95 (unch)

Celator® Pharmaceuticals to Present Data at the 56th American Society of Hematology Annual Meeting
PR Newswire - Mon Nov 24, 7:30AM CST
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that data for CPX-351, its lead product candidate, will be presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition in San Francisco, December 6-9, 2014.
CPXX: 1.95 (unch)

Celator Pharmaceuticals' (CPXX) CEO Scott Jackson on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 14, 2:02PM CST

CPXX: 1.95 (unch)

Celator Pharmaceuticals EPS in-line
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 3:22PM CST

CPXX: 1.95 (unch)

Celator® Pharmaceuticals Announces Business Update And Third Quarter 2014 Financial Results
PR Newswire - Thu Nov 13, 3:01PM CST
Celator Pharmaceuticals, Inc. (NASDAQ: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today reported business highlights and financial results for the third quarter ended September 30, 2014.
CPXX: 1.95 (unch)

Celator® Pharmaceuticals to Present at Stifel 2014 Healthcare Conference
PR Newswire - Thu Nov 06, 7:30AM CST
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that Scott Jackson, Chief Executive Officer, will present an overview of the company at the Stifel 2014 Healthcare Conference on November 19, 2014 at 4:10 p.m. ET in New York City.
CPXX: 1.95 (unch)

Celator Pharma reports November 13
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 12:13PM CST

CPXX: 1.95 (unch)

Celator® Pharmaceuticals to Report Third Quarter 2014 Financial Results on November 13, 2014
PR Newswire - Tue Nov 04, 11:20AM CST
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that it will host a conference call and live audio webcast on Thursday, November 13, 2014, at 4:30 p.m. ET to report third quarter 2014 financial results.
CPXX: 1.95 (unch)

Celator(R) Pharmaceuticals to Present on Liposome Delivery Systems at 2014 American Association of Pharmaceutical Scientists Annual Meeting
GlobeNewswire - Thu Oct 30, 7:30AM CDT
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that Dr. Lawrence Mayer, President, Founder and Chief Scientific Officer of Celator, will present at the 2014 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in San Diego, California on Wednesday, November 5, 2014, as part of the Advances in Lipid-Based Delivery Systems for Transdermal, Oral, and Parenteral Administered Drugs session. Dr. Mayer's presentation is scheduled at 2:50 p.m. PST/5:50 p.m. EST.
CPXX: 1.95 (unch)

Celator(R) Pharmaceuticals Announces Completion of Its Public Offering and the Exercise in Full of Option to Purchase Additional Units of Common Stock and Warrants to Purchase Common Stock
GlobeNewswire - Tue Oct 28, 9:49AM CDT
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced the closing of an underwritten public offering of 7,602,823 shares of common stock and warrants to purchase up to 760,282 shares of its common stock, including the exercise in full of the underwriters' over-allotment option to purchase up to an additional 991,673 units. The shares of common stock and warrants were offered in units consisting of one share of common stock and a warrant to purchase 0.10 of a share of common stock at a price of $1.95 per unit. The shares of common stock and the warrants are immediately separable and were issued separately. The warrants have an exercise price of $3.58 per whole share and have a term of five years. The net proceeds to Celator, after underwriting discounts and commissions and estimated offering expenses, were approximately $13.5 million.
CPXX: 1.95 (unch)

Celator(R) Pharmaceuticals Announces Phase 3 Clinical Study of CPX-351 Achieved Target Enrollment in High Risk (Secondary) Acute Myeloid Leukemia
GlobeNewswire - Mon Oct 27, 7:41AM CDT
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that the target enrollment of 300 patients has been achieved in the company's multicenter, randomized, open-label Phase 3 study of CPX-351 (cytarabine:daunorubicin) Liposome for Injection versus the current standard of care, conventional cytarabine and daunorubicin therapy (7+3) in patients with untreated high-risk (secondary) acute myeloid leukemia (AML). The study randomized the 300 patient ahead of schedule and will remain open for a short time to enable all patients currently in the process of referral and evaluation to complete enrollment into the study.
CPXX: 1.95 (unch)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 11:45AM CDT

IHT: 2.12 (unch), AIRM: 42.29 (-0.34), MGT: 0.71 (+0.02), NCT: 4.96 (-0.07), BBW: 20.57 (-0.11), ADHD: 3.41 (+0.16), CAB: 48.99 (-0.27), IPCM: 43.63 (-0.18), VII: 1.44 (unch), MTRN: 33.46 (-1.25), UTEK: 17.71 (+0.08), CPXX: 1.95 (unch), BRP: 23.01 (-0.33), SHLM: 37.32 (-0.90), NPTN: 3.13 (-0.03), IBIO: 0.69 (unch), YELP: 52.70 (+0.25), CLRO: 9.63 (-0.33), VPCO: 1.31 (+0.04), INFN: 14.05 (+0.05)

Celator(R) Pharmaceuticals Announces Pricing of a $12.9 Million Public Offering of Common Stock and Warrants to Purchase Common Stock
GlobeNewswire - Thu Oct 23, 6:09AM CDT
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced the pricing of an underwritten public offering of 6,611,150 shares of common stock and warrants to purchase up to 661,115 shares of its common stock. The shares of common stock and warrants are being offered in units consisting of one share of common stock and a warrant to purchase 0.10 of a share of common stock at a price of $1.95 per unit. The gross proceeds to Celator from this offering are expected to be approximately $12.9 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by the Company and exclusive of any warrant exercises. The shares of common stock and the warrants are immediately separable and will be issued separately. The warrants will be exercisable upon issuance at an exercise price of $3.58 per whole share and will have a term of five years. The Company has granted to the underwriters participating in the offering a 30-day option to purchase up to an additional 991,673 units to cover over-allotments, if any. The offering is expected to close on or about October 28, 2014, subject to customary closing conditions.
CPXX: 1.95 (unch)

Celator Pharmaceuticals to issue public offering of units
M2 - Mon Oct 20, 6:33AM CDT
Pharmaceutical company Celator Pharmaceuticals (NasdaqCM:CPXX) said on Friday that it plans to offer and sell shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering.
CPXX: 1.95 (unch)

Celator(R) Pharmaceuticals Announces Public Offering of Common Stock and Warrants to Purchase Common Stock
GlobeNewswire - Fri Oct 17, 11:58AM CDT
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that it intends to offer and sell shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. The shares of common stock and warrants are being offered in units consisting of one share of common stock and a warrant to purchase 0.10 of a share of common stock. Roth Capital Partners and National Securities Corporation are acting as joint book-running managers for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
CPXX: 1.95 (unch)

Celator(R) Pharmaceuticals to Present at BioCentury's 21st Annual NewsMakers in the Biotech Industry Conference
GlobeNewswire - Fri Sep 19, 7:30AM CDT
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that Scott Jackson, Chief Executive Officer, will present an overview of the company at BioCentury's 21 Annual NewsMakers in the Biotech Industry Conference on Friday, September 26, 2014 at 3:30 p.m. ET in New York City.
CPXX: 1.95 (unch)

Celator(R) Pharmaceuticals to Ring the NASDAQ Stock Market Closing Bell on September 17, 2014
GlobeNewswire - Wed Sep 17, 8:27AM CDT
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that the Celator team, led by Scott Jackson, Chief Executive Officer, will ring the NASDAQ Stock Market Closing Bell this afternoon. The ceremony is in recognition of the company listing on NASDAQ within the past year and to celebrate recent successes, including the development progress made with lead compound, CPX-351, and the decision to broaden potential clinical applications of the Company's proprietary CombiPlex(R) technology platform.
CPXX: 1.95 (unch)

Celator Pharmaceuticals Inc. (NASDAQ: CPXX) to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - Tue Sep 16, 9:06AM CDT
What:
CPXX: 1.95 (unch), NDAQ: 46.11 (-0.86)

Celator(R) Pharmaceuticals Announces Publication of Preclinical Data for CPX-351 in Acute Lymphoblastic Leukemia Models
GlobeNewswire - Mon Sep 15, 7:30AM CDT
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced the publication of preclinical data in Pediatric Blood & Cancer that further characterize the therapeutic potential of lead compound CPX-351 in hematological malignancies and support its ongoing clinical testing in pediatric patients with ALL. CPX-351 is currently being studied in a pivotal Phase 3 clinical trial in older patients with high risk (secondary) AML.
CPXX: 1.95 (unch)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 255

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 266

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 185

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 176

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 210

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 113

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 251

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 115

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 119

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 59

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading

Top 5 Most Recently Viewed Articles

Flora Growth Corp Sees 6% Surge in After-Hours Performance

Updated Category News Views 87

A Surge in After-Hours Trading for Flora Growth Corp Flora Growth Corp. (NASDAQ: FLGC) recently demonstrated significant volatility by surging 5.98% to $10.55 during after-hours trading. This movement came not long after closing at $9.96, which marked an increase of 3.59% earlier that day. Insights from Recent SEC Filing Regulation A Filing In a notable move, Flora Growth...

Continue Reading
Qubs Introduces Qubitunes, A New Interactive Audio Experience

Updated Category News Views 205

Qubs Launches Qubitunes for Creative Play Qubs has unveiled an exciting new product, Qubitunes, which has already won the 'Top Toy' award in the startup category at a prestigious Toy Fair. This innovative toy is set to transform playtime for children by offering a unique platform where they can express their creativity and dive into their own audio storytelling...

Continue Reading
Asyad Group's Expert Transport of Heavy Cryogenic Tank

Updated Category News Views 126

Asyad Group's Successful Transport of Cryogenic Tank Asyad Group has recently completed a remarkable international transport operation, successfully moving a 115 metric ton pressurized cryogenic tank from Northern India to a major destination in Saudi Arabia. This endeavor highlights the Group's expertise in cross-border logistics. A Journey of Precision The transport...

Continue Reading
Famous Toastery Launches Holiday Fundraising Efforts

Updated Category News Views 134

Famous Toastery's Compassionate Campaign for Local Communities The Famous Toastery, known for its delightful breakfast and brunch offerings, is stepping up this holiday season with a noble initiative aimed at fighting hunger. This renowned franchise is collaborating with Feeding the Carolinas, encouraging guests to make donations that will significantly impact individuals...

Continue Reading
Jiayin Group's Upcoming Earnings Call Set for November 25, 2025

Updated Category News Views 190

Jiayin Group Inc. Announces Q3 2025 Financial Results Release Jiayin Group Inc. (NASDAQ: JFIN), a prominent fintech platform in China, has shared significant news that it will unveil its unaudited financial outcomes for the third quarter of 2025. This crucial announcement is set to occur before the U.S. markets open on November 25, 2025. The anticipation surrounding these...

Continue Reading